Irish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Leathanach 1 ó 403 torthaí
Methods of treating developmental disorders and/or seizure disorders with etifoxine
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
TECHNICAL FIELD
Methods of treating developmental disorders and/or seizure disorders with etifoxine are provided.
BACKGROUND
Treatments for developmental disorders such as Autistic Spectrum Disorder, Dravet syndrome, Rett syndrome, Angelman syndrome, Fragile X syndrome, and Fragile X-associated
Compounds of use in the treatment of epilepsy, seizure, and electroconvulsive disorders
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
FIELD OF THE INVENTION
The present invention relates to bridged dianilino compounds and pharmaceutical compositions and method of use thereof for the prevention and treatment of epilepsies, seizures, and other electroconvulsive disorders. Specifically, this invention relates to the use of
Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
BACKGROUND OF THE INVENTION
This invention was made with Government support under contract AI47822 and GM37734. The government has certain rights in this invention.
A seizure is a paroxysmal event due to abnormal, excessive, hypersynchronous discharges from an aggregate of central nervous system
Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
BACKGROUND OF THE INVENTION
A seizure is a paroxysmal event due to abnormal, excessive, hypersynchronous discharges from an aggregate of central nervous system (CNS) neurons, while epilepsy is a condition in which a person has recurrent seizures due to a chronic, underlying process. Experimental and
Agmatine and agmatine analogs in the treatment of epilepsy, seizure, and electroconvulsive disorders
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
FIELD OF THE INVENTION
The present invention relates to the use of agmatine and analogs thereof in the prevention and treatment of epilepsies, seizures, and other electroconvulsive disorders.
BACKGROUND OF THE INVENTION
Epilepsy is a general term describing brain disorders that are characterized by
Methods of treating seizure disorders
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
TECHNICAL FIELD
Methods of treating seizure disorders are provided.
BACKGROUND
Seizure disorders typically involve abnormal nerve cell activity in the brain, causing seizures which may be manifested by periods of unusual behavior, sensations, diminished consciousness and sometimes loss of
Method of treating a human being for a class of neurological defects and seizure disorders
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
BACKGROUND OF THE INVENTION
1. Field of Invention
This invention relates to treatment of human beings for conditions associated with deficiencies in the N-6-trimethyl-L-lysine (TML) pathway affecting biosynthesis of carnitine. Such conditions include: (1) seizures, myoclonic seizures, epilepsy,
KCNQ2 and KCNQ3--potassium channel genes which are mutated in benign familial neonatal convulsions (BFNC) and other epilepsies
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
BACKGROUND OF THE INVENTION
Epileptic disorders affect about 20 to 40 million people worldwide. Generalized idiopathic epilepsies (IGE) cause 40% of all epileptic disorders and commonly have a genetic basis (Plouin, 1994). Most of the IGEs that are inherited are complex, non-monogenic diseases. One
KCNQ2 and KCNQ3--potassium channel genes which are mutated in benign familial neonatal convulsions (BFNC) and other epilepsies
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
BACKGROUND OF THE INVENTION
Epileptic disorders affect about 20 to 40 million people worldwide. Generalized idiopathic epilepsies (IGE) cause 40% of all epileptic disorders and commonly have a genetic basis (Plouin, 1994). Most of the IGEs that are inherited are complex, non-monogenic diseases. One
Treatment of seizure disorders and pharmaceutical compositions useful therein
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
Gamma-aminobutyric acid (GABA) is a major inhibitory neurotransmitter of the CNS. Various theories have been advanced to implicate deficiencies in GABA-mediated neuronal inhibition as a contributing factor in the pathogenesis of seizure disorders, such as epilepsy. In laboratory animals, a decrease
Treatment of seizure disorders and pharmaceutical compositions useful therein
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
Gamma-aminobutyric acid (GABA) is a major inhibitory neurotransmitter of the CNS. Various theories have been advanced to implicate deficiencies in GABA-mediated neuronal inhibition as a contributing factor in the pathogenesis of seizure disorders, such as epilepsy. In laboratory animals, a decrease
Methods for treating seizure disorders and pain
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
BACKGROUND OF THE INVENTION
Epilepsy, a complex neurological disorder estimated to affect over 50 million people worldwide, is characterized by recurrent spontaneous seizures due to neuronal hyperexcitability and hypersynchronous neuronal firing. Despite the availability of more than 20
Seizure disorder evaluation based on intracranial pressure and patient motion
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
TECHNICAL FIELD
The disclosure relates to patient monitoring, and, more particularly, to collecting information to evaluate a patient condition.
BACKGROUND
Some neurological disorders, such as epilepsy, are characterized by the occurrence of seizures. Seizures may be attributable to abnormal
Apparatus and method for detecting epilepsy seizure
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
BACKGROUND OF THE INVENTION
The present invention relates to an apparatus and method for detecting an epilepsy seizure.
A brain wave is obtained by measuring a change in potential difference caused by a weak electrical activity of the brain by means of scalp electrodes or intracranial electrodes or
Apparatus and method for detecting epilepsy seizure
Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
This application claims the priority benefit under 35 U.S.C. .sctn.119 of Japanese Patent Application No. 2012-0067709 (filed on Mar. 23, 2012), which is hereby incorporated in its entirety by reference.
BACKGROUND OF THE INVENTION
The present invention relates to an apparatus and method for
An bunachar luibheanna míochaine is iomláine le tacaíocht ón eolaíocht
- Oibreacha i 55 teanga
- Leigheasanna luibhe le tacaíocht ón eolaíocht
- Aitheantas luibheanna de réir íomhá
- Léarscáil GPS idirghníomhach - clibeáil luibheanna ar an láthair (ag teacht go luath)
- Léigh foilseacháin eolaíochta a bhaineann le do chuardach
- Cuardaigh luibheanna míochaine de réir a n-éifeachtaí
- Eagraigh do chuid spéiseanna agus fanacht suas chun dáta leis an taighde nuachta, trialacha cliniciúla agus paitinní
Clóscríobh symptom nó galar agus léigh faoi luibheanna a d’fhéadfadh cabhrú, luibh a chlóscríobh agus galair agus comharthaí a úsáidtear ina choinne a fheiceáil.
* Tá an fhaisnéis uile bunaithe ar thaighde eolaíoch foilsithe
